These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23938375)

  • 1. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
    Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
    Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
    Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
    Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
    Backes FJ; Leon ME; Ivanov I; Suarez A; Frankel WL; Hampel H; Fowler JM; Copeland LJ; O'Malley DM; Cohn DE
    Gynecol Oncol; 2009 Sep; 114(3):486-90. PubMed ID: 19515405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lynch syndrome-related endometrial carcinoma].
    Pang SJ; Guo DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):494-7. PubMed ID: 22932468
    [No Abstract]   [Full Text] [Related]  

  • 8. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High homogeneity of MMR deficiency in ovarian cancer.
    Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
    Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
    Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
    Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.
    Joehlin-Price AS; Perrino CM; Stephens J; Backes FJ; Goodfellow PJ; Cohn DE; Suarez AA
    Gynecol Oncol; 2014 Apr; 133(1):43-7. PubMed ID: 24444820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
    Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
    Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
    Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
    Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6.
    Hegan DC; Narayanan L; Jirik FR; Edelmann W; Liskay RM; Glazer PM
    Carcinogenesis; 2006 Dec; 27(12):2402-8. PubMed ID: 16728433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
    Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
    Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
    Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
    Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
    Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
    J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.